Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues:
Products, net	$ 124,926	$ 100,448
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration	$ 22,005	$ 13,226
Total revenues	146,931	113,674
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	22,346	12,622
Research and development	195,149	136,144
Selling, general and administrative	71,131	82,768
Settlement and license charges	10,000
Amortization of in-licensed rights	170	166
Total cost and expenses	298,796	231,700
Operating loss	(151,865)	(118,026)
Other (loss) income:
Other expense, net	(15,528)	(7,420)
Gain from sale of Priority Review Voucher		108,069
Total other (loss) income	(15,528)	100,649
Loss before income tax (benefit) expense	(167,393)	(17,377)
Income tax (benefit) expense	(143)	115
Net loss	(167,250)	(17,492)
Other comprehensive (loss) income:
Unrealized (losses) gains on investments, net of tax	(6)	574
Total other comprehensive (loss) income	(6)	574
Comprehensive loss	$ (167,256)	$ (16,918)
Net loss per share - basic and diluted	$ (2.10)	$ (0.23)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	79,454	76,432